Entrada Therapeutics, Inc. (TRDA)
TRDA moved a median of -0.32% 30 minutes after news, and -0.44% by the close. How TRDA actually reacts to news — the realized, point-in-time move the market made, measured across 344 labeled events over the last three years with zero look-ahead.
TRDA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 338 |
| 30-min | -0.32% | 37% | 344 |
| 60-min | -0.55% | 39% | 344 |
| to close | -0.44% | 44% | 343 |
| Middle 50% of TRDA reactions | -1.49% to +0.50% |
|---|---|
| Median reaction (30-min) | -0.32% |
| Measured reactions | 344 |
Half of all Entrada Therapeutics, Inc. news events land between -1.49% and +0.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TRDA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | -0.68% | 30% | -0.66% |
| Coverage initiations | 14 | 0.00% | 43% | +3.77% |
| Rating reiterations | 29 | -0.09% | 38% | +0.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how TRDA ranks against every other measured name →
That’s how TRDA usually reacts — get an email when it moves on news →Email me when TRDA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TRDA's baseline. Nothing else.
Recent TRDA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 | Press release | GlobeNewswire | +0.85% | -2.98% | |
| Form 8-K Entrada Therapeutics, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | -2.98% | |
| Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study | Press release | GlobeNewswire | +0.85% | -2.98% | |
| Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program | Press release | GlobeNewswire | -1.57% | -8.29% | |
| Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.16% | -1.92% | |
| Entrada Therapeutics Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -3.08% | -5.49% | |
| Form 10-Q Entrada Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.08% | -5.49% | |
| Form 8-K Entrada Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -3.08% | -5.49% | |
| Form 8-K Entrada Therapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -1.17% | +5.70% | |
| Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study | Press release | GlobeNewswire | -0.88% | -2.35% | |
| Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.88% | -2.35% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (TRDA) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.38% | +2.48% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.72% | -1.34% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.30% | -0.45% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.70% | +1.36% | |
| Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.15% | -1.80% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.75% | +0.33% | |
| Form 8-K Entrada Therapeutics, For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -3.08% | -3.58% | |
| Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -1.48% | -2.32% | |
| Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.39% | -7.39% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.00% | -0.63% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.58% | -0.58% | |
| Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study | Press release | GlobeNewswire | -14.81% | +0.44% | |
| Entrada Therapeutics Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -14.81% | +0.44% | |
| Form 10-Q Entrada Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -14.81% | +0.44% | |
| Form 8-K Entrada Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -14.81% | +0.44% | |
| Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 | Press release | GlobeNewswire | -14.81% | +0.44% | |
| Form DEFA14A Entrada Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.16% | -0.23% | |
| Form ARS Entrada Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.29% | -1.56% | |
| Form DEF 14A Entrada Therapeutics, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -1.29% | -1.56% | |
| Form DEFA14A Entrada Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.29% | -1.56% | |
| Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +4.31% | |
| Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -0.09% | +10.35% | |
| Form 10-K Entrada Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.09% | +10.35% | |
| Form 8-K Entrada Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | +10.35% | |
| Form S-8 Entrada Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.09% | +10.35% | |
| Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study | Press release | GlobeNewswire | +0.46% | +0.82% | |
| Entrada Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.04% | -9.00% | |
| Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases | Press release | GlobeNewswire | +0.66% | -0.76% | |
| Form 8-K Entrada Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | -0.76% | |
| Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.44% | -1.23% | |
| Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.10% | +1.18% | |
| Form EFFECT Entrada Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -2.21% | +2.21% | |
| Entrada Therapeutics Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -1.84% | +2.21% | |
| Form 10-Q Entrada Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.84% | +2.21% | |
| Form 8-K Entrada Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.84% | +2.21% | |
| Form S-3 Entrada Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.84% | +2.21% | |
| Entrada Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -1.22% | +0.00% | |
| Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program | Press release | GlobeNewswire | +0.95% | +0.57% | |
| Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.19% | -1.30% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TRDA section they belong to.
Where else TRDA is measured.
TRDA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Entrada Therapeutics, Inc.'s median reaction calculated?
Every labeled TRDA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 344 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of TRDA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TRDA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.